The future of engagement won’t be defined by how much information reaches health care professionals, but by how precisely it supports the decision at hand.
Commentary|Articles|October 7, 2026
Why Pharma’s Next Communications Model Won’t Be a Cascade
Author(s)Kishan Rees, M.D.
How the proposed lateral network can change the traditional mindset around communications and pharma’s role in today’s new flow of health information.
Advertisement
Advertisement
In my
Related to this article
Dr. Jeremy Levin joins Ken Banta to share why he believes biotech's future demands a new level of leadership and stakeholder education — and why "mission without method" is a wasted effort.
Why purpose is becoming the most important infrastructure in AI-driven health care technology.
As Japan prices take on greater global significance, disciplined launch strategy can help pharma companies capture the full value of innovation.
Social listening can help medical affairs and medical information teams identify knowledge gaps, strengthen scientific exchange and respond to changing stakeholder needs faster and at greater scale.
CORXEL’s Dr. Bo Liang on why GLP-1 therapies are a broader chronic disease platform — not just obesity drugs — with benefits across cardiovascular, renal, and metabolic disease.
How earlier signals of misconnection may help pharma identify trust breakdowns before they show up as lagging measures in adherence, initiation, engagement, and outcomes.
Why GLP-1s achieving bariatric surgery-level efficacy is the field's most surprising advancement of the past decade.
Advertisement
Advertisement